CB2 Insights Completes Reverse Take-over Transaction, to List on Canadian Securities Exchange Under Symbol “CBII”
Leading Data Company Focused on Medical Cannabis to Commence Trading on March 6
TORONTO, March 01, 2019 (GLOBE NEWSWIRE) — CB2 Insights (“CB2” or the “Company”), a leading provider of predictive analytics tools, data-driven software and services across the cannabis value chain, today announced that it has completed its reverse take-over transaction with MVC Technologies Inc. On February 26th the Canadian Securities Exchange (“CSE”) issued its conditional listing approval for the listing of the Company’s common shares. The common shares are expected to commence trading on March 6th, 2019 under the ticker “CBII”.
As is key to any industry, the ancillary market poses some of the most exciting growth opportunities in the cannabis market. As we continue to strengthen our clinical arm in the United States and drive a new level of real-world evidence related to the efficacy of medical cannabis treatment, we are proud to have a solid financial foundation to drive a new level of insights to uncover the place that medical cannabis has in the traditional healthcare market.
Prad Sekar, CEO of CB2 Insights
CB2 Insights works to help mainstream cannabis into traditional healthcare through objective, real-world evidence driven from its wholly-owned clinical arm. With more than 300,000 patient interactions to-date, the company is able to apply standard data collection protocols and track the efficacy of cannabis treatments in a way currently not available within the cannabis industry today. The Company owns and operates the largest and longest-running, multi-state medical cannabis evaluation and education center serving 12 states across the US. The Company has an aggressive medical cannabis clinic consolidation strategy and anticipates further announcements in this regard in the coming quarters.
Sekar continued, “As the market turns its focus to investments in ancillary cannabis services, we are committed to our growth strategies across the US and assessing international markets. In addition, we are focused on the development of new predictive analytics tools that the industry urgently needs to bring about a greater maturation of insights to producers, retailers, clinicians, patients, consumers, educational institutions and regulatory bodies. I sincerely appreciate our international team for their dedication and outstanding execution that has helped CB2 Insights reach this milestone.”
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and clinical service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry. To date, the Company has collected data from more than 300,000 patient interactions.
For more information please visit www.cb2insights.com.
